BRIEF-FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Reuters2026/09/24 19:21Sept 24 (Reuters) - FDA:
FDA APPROVES BELZUTIFAN IN COMBINATION WITH LENVATINIB FOR ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT
FDA: RECOMMENDED DOSAGE IS 20 MG OF LENVATINIB IN COMBINATION WITH 120 MG OF BELZUTIFAN ONCE DAILY UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY
Further company coverage: MRK.N
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japan Central Bank inflation indicators accelerate, providing grounds for further interest rate hikes
An indicator used by the Bank of Japan to measure underlying inflation accelerated last month, significantly exceeding its target level, providing further justification for continuing to raise the benchmark interest rate.
Hut 8 Wins $140M Bid For Poolin’s Texas Data Centers
Euro: Volatility divergence points to future swings against US Dollar – Commerzbank
Tesla (TSLA.US) officially announces mass production and delivery of Semi electric trucks, reiterating annual production target of 50,000 units
Tesla (TSLA.US) announced the start of mass production and deliveries for the Semi electric truck.
Crypto prices
More
